Abstract 443P
Background
The low survival rate of cancer patients, especially patients who got metastases, necessitates an approach in providing additional therapy that is safe, capable of delaying disease progression, and prolonging patient survival. Vitamin D is an adjunctive therapy that is easy to obtain and shows anti-neoplastic activity against cancer so that it can reduce mortality. This study aimed to conduct a systematic review and meta-analysis regarding the efficacy of vitamin D supplementation in overall survival (OS) of cancer patients.
Methods
A systematic search of various databases up to end of 2022 was conducted to identify Randomized Controlled Trials (RCTs) involving the efficacy of vitamin D supplementation in OS of cancer patients. By using a random effect model, pooled hazard ratios (HR) with 95% confidence intervals (CI) were calculated to determine the values of OS. In formulating the study problem, we determine the study questions based on the study background, which consists of the populations (P), interventions (I), comparisons (C), and outcomes (O). The populations were cancer patients. The intervention was administration of vitamin D supplementation. The comparison was no administration of vitamin D supplementation. The outcome was OS. The RCTs having cancer patients over 18 years of age with available and sufficient information about OS were the inclusion criteria of this study. Study that has participants taking vitamin D supplementation regularly, and ongoing study with results not presented or published at the time of the literature search were the exclusion criteria of this study.
Results
Of the six RCTs, analysis was performed on 1,916 cancer patients in this study. In terms of survival, statistically, there was no difference in OS [HR 0.97, 95% CI 0.74 – 1.28, p = 0.85] between vitamin D supplementation and no supplementation in cancer patients.
Conclusions
Although vitamin D supplementation does not improve OS in cancer patients, is could be considered because it still shows benefits for cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Internal Medicine, Faculty of Medicine, Sam Ratulangi University / Prof. dr. R. D. Kandou General Hospital, Manado, Indonesia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract